with 40 to 50 degree and could be changed by the assistants according to the requirement of the operators.
The enrollment of the optimal external laryngeal manipulation to improve laryngeal views was required in some cases of both groups. We agree that the placement of the flashlight (Fenixlight Limited, Shenzhen, China) itself may have a positive effect on the exposure of the glottis compared the patient without any external laryngeal manipulation in direct laryngoscopy group.
As regards the letter from Dr. Cherng, we agree as noted above that placement of the flashlight and any pressure applied could have altered or improved exposure of the glottis. In Reply: I appreciate the comments by Dexter and Epstein regarding our publication on optimizing preoperative blood ordering. 1 In their comment, they pose the question of whether our recommended maximum surgical blood order schedule would be changed if we applied the criteria published in their own study. 2 The answer is that I do not know whether our recommendations would be changed because Dexter and Epstein's methods are somewhat complicated and difficult to understand. Our primary goal was to develop an algorithm that was simple and easy for other institutions to apply using their own data from an anesthesia information management system. In addition, I believe that our methods are more reliable because our algorithm does not rely as heavily on estimated blood loss (EBL), a parameter that most clinicians recognize as a crude measure that is fraught with error. In our algorithm, EBL was complimented by two other measurespercentage of patients receiving erythrocyte transfusion and the average number of erythrocyte units per patient-two variables that are much more objective and easy to determine from electronic anesthesia records.
limit for the incidence of transfusion … For each of the scheduled procedures for which the calculated value … is less than 5.0% and for which there are 19 or more cases, set the MSBOS to indicate no type and screen."
Thus, the value of 50 ml was to be determined statistically for each hospital; our criterion was less than 50 ml not larger than 50 ml; and we did not use 5% but the lower confidence limit of 5%. The criterion of less than 50 ml versus larger than 50 ml had a substantive effect at our studied hospital because the EBL often were reported using rounded values (e.g., not 49 ml but 50 ml). 2 If the authors 1 apply the criteria that we published, are any of their hospital's maximum surgical blood ordering schedule recommendations changed? 
Applying Systematic Criteria for Type and Screen Based on Procedure's Probability of Erythrocyte Transfusion
To the Editor: Frank et al. 1 describe development of a maximum surgical blood ordering schedule. We are pleased that they used our findings 2 regarding choice of whether to perform Type and Screen preoperatively. From the authors: 1 "Using previously proposed criteria, we developed an algorithm … to determine the appropriate preoperative blood order for each procedure category. These criteria included: 5% or more of patients transfused with erythrocytes 2 ; median estimated blood loss (EBL) more than 50 ml 2 ; and a transfusion index 0.3 or more."
Although the reliability and validity of the first two of the criteria refer to our article, 1,2 our table 1 summary of our Results was different:
"Select a threshold for 'minimal EBL' (e.g., 50 ml) by using the smallest median EBL with many scheduled procedures and cases for which the lower 95% confidence limit for the incidence of erythrocyte transfusion was more than 5.0% … For each of the scheduled procedures with median EBL … less than [this] threshold … calculate the lower 95% confidence Correspondence Correspondence Vienna, Austria) as a quick reversal agent in emergency situations. Levy et al. cited the study by Marlu et al. 2 but made no mention of the results on FEIBA as a reversal agent reported in that study and chose only to discuss the results on prothrombin complex concentrate and recombinant factor VIIa, while acknowledging that there is an activated form of 4-factor prothrombin complex concentrate.
Factor eight inhibitor bypass activity consists of nonactivated factors II, IX, X, and activated VII, which means that it is similar to 3-factor prothrombin complex concentrate and recombinant factor VIIa combined. It is inexpensive and has been used extensively and successfully in the management of patients with hemophilia A with inhibitors for several decades in many countries, including the United States, 3,4 although FEIBA appears not to have been approved by the Food and Drug Administration yet. In the ex vivo study in healthy white males by Marlu et al., 2 rivaroxaban reduced total and peak thrombin generation, as well as time to initiation of thrombin generation. Prothrombin complex concentrate normalized total thrombin generation but not the peak thrombin value or thrombin generation starting time. Recombinant factor VIIa corrected thrombin generation starting time but not total quantity or peak. Interestingly, FEIBA corrected all parameters at lower doses and overcorrected at higher doses. These authors also demonstrated a dose-dependent correction by FEIBA of the thrombin generation starting time prolonged by dabigatran. Their conclusion was that FEIBA at lower doses seems to be the most reasonable approach to novel oral anticoagulant reversal. 2 Published a month before Levy et al.'s review was a case report from Davis, California, of a middle-aged man on dabigatran 150 mg two times per day who sustained a transseptal perforation during atrial ablation. 5 Within 60 min, approximately 4.5 l of blood was removed via pericardiocentesis. Intravenous low-dose FEIBA (3,159 units, 26 U/kg) over 15 min was administered. Hemostasis was noted within minutes of initiating the infusion with cessation of bleeding occurring soon after.
Several abstracts have also been published documenting improvement in bleeding parameters by FEIBA in novel oral anticoagulant-treated animals. 6
Factor Eight Inhibitor Bypass Activity for Novel Oral Anticoagulant Reversal
To the Editor: In their excellent review on novel oral anticoagulants, Levy et al. 1 seemed to have deliberately ignored the potential of factor eight inhibitor bypass activity (FEIBA; Baxter AG, The second question posed in their letter to the editor is why we used EBL greater than 50 ml in our algorithm to indicate the need for type and screen, whereas their study used EBL less than 50 to indicate no need for type and screen. This question is really about what to do with cases where EBL is 50 ml. We recognized that EBL is almost always reported as rounded values, and we made the decision to put cases with EBL of 50 ml in the "no type and screen" category, as long as the percentage of patients transfused was less than 5% and the transfusion index (average units/patient) was less than 0.3. This decision was based on the observation that many anesthesia providers enter "50" when EBL is minimal, because the electronic anesthesia records do not allow a text entry for EBL. In Dexter and Epstein's proposed algorithm, the cases with EBL of 50 would be more likely to have a type and screen ordered, because they used EBL less than 50 as a criterion not to order a type and screen.
In summary, it is difficult to compare our maximum surgical blood order schedule with Dexter and Epstein's study because our algorithms have more differences than similarities. In addition, our publication included the actual maximum surgical blood order schedule as an appendix, whereas theirs did not, making the comparison even more difficult. I can report, however, that our type and crossmatch to transfusion ratio has decreased by 29% since the release of the maximum surgical blood order schedule at our institution. This is the evidence that we have effectively reduced unnecessary blood orders, which will decrease cost, and perhaps improve patient safety, because the blood bank personnel can now focus on completing the blood orders for patients who may actually need transfusion.
